PRDX5 and prostate cancer: The results showed that PRDX5‐Nomo had the highest C‐index for predicting BCR for prostate cancer in CancerMap and GSE70769, ranked second in the TCGA, fifth in the DKFZ, and eighth in the GSE54460.